788 related articles for article (PubMed ID: 27866858)
1. Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson's disease: a cohort study.
Schrag A; Siddiqui UF; Anastasiou Z; Weintraub D; Schott JM
Lancet Neurol; 2017 Jan; 16(1):66-75. PubMed ID: 27866858
[TBL] [Abstract][Full Text] [Related]
2. CSF β-amyloid
Kim R; Lee J; Kim HJ; Kim A; Jang M; Jeon B; Kang UJ
Neurology; 2019 Jan; 92(1):e40-e47. PubMed ID: 30504429
[TBL] [Abstract][Full Text] [Related]
3. CSF β-Amyloid 1-42 Predicts Progression to Cognitive Impairment in Newly Diagnosed Parkinson Disease.
Terrelonge M; Marder KS; Weintraub D; Alcalay RN
J Mol Neurosci; 2016 Jan; 58(1):88-92. PubMed ID: 26330275
[TBL] [Abstract][Full Text] [Related]
4. CSF tau and tau/Aβ42 predict cognitive decline in Parkinson's disease.
Liu C; Cholerton B; Shi M; Ginghina C; Cain KC; Auinger P; ; Zhang J
Parkinsonism Relat Disord; 2015 Mar; 21(3):271-6. PubMed ID: 25596881
[TBL] [Abstract][Full Text] [Related]
5. Predicting cognitive decline with non-clinical markers in Parkinson's disease (PRECODE-2).
Yousaf T; Pagano G; Niccolini F; Politis M
J Neurol; 2019 May; 266(5):1203-1210. PubMed ID: 30820739
[TBL] [Abstract][Full Text] [Related]
6. Predictors of cognitive impairment in newly diagnosed Parkinson's disease with normal cognition at baseline: A 5-year cohort study.
Chen J; Zhao D; Wang Q; Chen J; Bai C; Li Y; Guo X; Chen B; Zhang L; Yuan J
Front Aging Neurosci; 2023; 15():1142558. PubMed ID: 36926634
[TBL] [Abstract][Full Text] [Related]
7. Olfactory impairment predicts cognitive decline in early Parkinson's disease.
Fullard ME; Tran B; Xie SX; Toledo JB; Scordia C; Linder C; Purri R; Weintraub D; Duda JE; Chahine LM; Morley JF
Parkinsonism Relat Disord; 2016 Apr; 25():45-51. PubMed ID: 26923521
[TBL] [Abstract][Full Text] [Related]
8. Cerebrospinal fluid GFAP is a predictive biomarker for conversion to dementia and Alzheimer's disease-associated biomarkers alterations among de novo Parkinson's disease patients: a prospective cohort study.
Liu T; Zuo H; Ma D; Song D; Zhao Y; Cheng O
J Neuroinflammation; 2023 Jul; 20(1):167. PubMed ID: 37475029
[TBL] [Abstract][Full Text] [Related]
9. CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study.
Alves G; Brønnick K; Aarsland D; Blennow K; Zetterberg H; Ballard C; Kurz MW; Andreasson U; Tysnes OB; Larsen JP; Mulugeta E
J Neurol Neurosurg Psychiatry; 2010 Oct; 81(10):1080-6. PubMed ID: 20547614
[TBL] [Abstract][Full Text] [Related]
10. CSF biomarkers and clinical progression of Parkinson disease.
Hall S; Surova Y; Öhrfelt A; Zetterberg H; Lindqvist D; Hansson O
Neurology; 2015 Jan; 84(1):57-63. PubMed ID: 25411441
[TBL] [Abstract][Full Text] [Related]
11. Ratios of proteins in cerebrospinal fluid in Parkinson's disease cognitive decline: prospective study.
Delgado-Alvarado M; Dacosta-Aguayo R; Navalpotro-Gómez I; Gago B; Gorostidi A; Jiménez-Urbieta H; Quiroga-Varela A; Ruiz-Martínez J; Bergareche A; Rodríguez-Oroz MC
Mov Disord; 2018 Nov; 33(11):1809-1813. PubMed ID: 30423201
[TBL] [Abstract][Full Text] [Related]
12. CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study.
Kang JH; Mollenhauer B; Coffey CS; Toledo JB; Weintraub D; Galasko DR; Irwin DJ; Van Deerlin V; Chen-Plotkin AS; Caspell-Garcia C; Waligórska T; Taylor P; Shah N; Pan S; Zero P; Frasier M; Marek K; Kieburtz K; Jennings D; Tanner CM; Simuni T; Singleton A; Toga AW; Chowdhury S; Trojanowski JQ; Shaw LM;
Acta Neuropathol; 2016 Jun; 131(6):935-49. PubMed ID: 27021906
[TBL] [Abstract][Full Text] [Related]
13. Associations between Cerebrospinal Fluid Biomarkers and Cognition in Early Untreated Parkinson's Disease.
Skogseth RE; Bronnick K; Pereira JB; Mollenhauer B; Weintraub D; Fladby T; Aarsland D
J Parkinsons Dis; 2015; 5(4):783-92. PubMed ID: 26599300
[TBL] [Abstract][Full Text] [Related]
14. Clinical criteria for subtyping Parkinson's disease: biomarkers and longitudinal progression.
Fereshtehnejad SM; Zeighami Y; Dagher A; Postuma RB
Brain; 2017 Jul; 140(7):1959-1976. PubMed ID: 28549077
[TBL] [Abstract][Full Text] [Related]
15. Montreal Cognitive Assessment for the screening and prediction of cognitive decline in early Parkinson's disease.
Kandiah N; Zhang A; Cenina AR; Au WL; Nadkarni N; Tan LC
Parkinsonism Relat Disord; 2014 Nov; 20(11):1145-8. PubMed ID: 25176439
[TBL] [Abstract][Full Text] [Related]
16. An increased rate of longitudinal cognitive decline is observed in Parkinson's disease patients with low CSF Aß42 and an APOE ε4 allele.
Shahid M; Kim J; Leaver K; Hendershott T; Zhu D; Cholerton B; Henderson VW; Tian L; Poston KL
Neurobiol Dis; 2019 Jul; 127():278-286. PubMed ID: 30826425
[TBL] [Abstract][Full Text] [Related]
17. Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls.
Mollenhauer B; Caspell-Garcia CJ; Coffey CS; Taylor P; Shaw LM; Trojanowski JQ; Singleton A; Frasier M; Marek K; Galasko D;
Neurology; 2017 Nov; 89(19):1959-1969. PubMed ID: 29030452
[TBL] [Abstract][Full Text] [Related]
18. CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease.
Siderowf A; Xie SX; Hurtig H; Weintraub D; Duda J; Chen-Plotkin A; Shaw LM; Van Deerlin V; Trojanowski JQ; Clark C
Neurology; 2010 Sep; 75(12):1055-61. PubMed ID: 20720189
[TBL] [Abstract][Full Text] [Related]
19. Machine learning-based prediction of longitudinal cognitive decline in early Parkinson's disease using multimodal features.
Almgren H; Camacho M; Hanganu A; Kibreab M; Camicioli R; Ismail Z; Forkert ND; Monchi O
Sci Rep; 2023 Aug; 13(1):13193. PubMed ID: 37580407
[TBL] [Abstract][Full Text] [Related]
20. REM behavior disorder predicts motor progression and cognitive decline in Parkinson disease.
Pagano G; De Micco R; Yousaf T; Wilson H; Chandra A; Politis M
Neurology; 2018 Sep; 91(10):e894-e905. PubMed ID: 30089615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
